ReviewFrontiers in microbiology2021
Durlobactam, a New Diazabicyclooctane β-Lactamase Inhibitor for the Treatment of
Review in Frontiers in microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 1 synthesis or guideline pooled it, 72 citations in OpenAlex.
- Drug-resistantClinical microbiology reviews · 2025Pooled it
- Sulbactam-durlobactam and cefiderocol combination treatment ofAntimicrobial agents and chemotherapy · 2026Article
- Carbapenemases: epidemiology, detection and management in a changing global landscape.JAC-antimicrobial resistance · 2026Review
- Redefining Antimicrobial Resistance inInternational journal of molecular sciences · 2026Review
- Sulbactam-Durlobactam in the Treatment of Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2026Review
- New Insights intoPathogens (Basel, Switzerland) · 2026Review
- Precision Approaches to Carbapenem-Resistant Infections in the ICU: Integrating Diagnostics, Stewardship, and Novel Therapies.Diagnostics (Basel, Switzerland) · 2026Review
- Structural perspectives on clinical β-lactamase inhibitors: From mechanism to resistance.Journal of microbiology (Seoul, Korea) · 2026Review
- Monotherapy versus combination therapy for treatment of carbapenem-resistant Acinetobacter baumannii complex infections: results from an observational study.Critical care science · 2026Observational
- A Review ofInternational journal of microbiology · 2026Review
- A 4-methyl-substituted durlobactam analogue as a potential class-D oxacillinase inhibitor inFrontiers in bioinformatics · 2026Article
- Successful treatment of carbapenem-resistantAME case reports · 2026Article
- Activity of ampicillin-sulbactam, sulbactam-durlobactam, and comparators againstAntimicrobial agents and chemotherapy · 2025Article
- A microbiological and structural analysis of the interplay between sulbactam/durlobactam and imipenem against penicillin-binding proteins (PBPs) ofAntimicrobial agents and chemotherapy · 2025Article
- Restoring ceftolozane susceptibility: a role for diazabicyclooctane β-lactamase inhibitors?Antimicrobial agents and chemotherapy · 2025Article
- Review
- Sulbactam-Durlobactam: A Novel Antibiotic Combination for the Treatment ofThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2025Review
- Differences in Patient Access to Newly Approved Antibacterial Drugs in EU/EEA Countries.Antibiotics (Basel, Switzerland) · 2024Review
- Flexible Development Programs for Antibacterial Drugs to Address Unmet Medical Needs.Emerging infectious diseases · 2024Review
- An overview of sulbactam-durlobactam approval and implications in advancing therapeutics for hospital-acquired and ventilator-associated pneumonia byHealth science reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Durlobactam is a new member of the diazabicyclooctane class of β-lactamase inhibitors with broad spectrum activity against Ambler class A, C, and D serine β-lactamases. Sulbactam is a first generation β-lactamase inhibitor with activity limited to a subset of class A enzymes that also has direct-acting antibacterial activity against
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.